Excerpt
Methods: Data from patients admitted for severe sepsis or septic shock to Japanese ICUs were retrospectively collected from Jan 2011 to Dec 2013 through the J-SEPTIC DIC (Japanese society of education for physicians and trainees in intensive care disseminated intravascular coagulation) study data base set. We analyzed the potential benefit of PMX-DHP using a propensity score–matched (1:1) cohort analysis in septic shock patients.
Results: Of 1754 eligible patients, 522 underwent PMX-DHP. Propensity score matching created a matched cohort of 640 patients (320 pairs with and without PMX-DHP). There was no significant difference between the two matched cohorts for the ICU mortality (PMX-DHP; 24.4% vs non-PMX-DHP; 25.9%, p=0.650). On the other hand PMX-DHP treatment was significant improvement of the hospital mortality compared with non-PMX-DHP treatment (PMX-DHP; 33.1% vs non-PMX-DHP; 43.4%, p=0.01).
Conclusions: In this demonstrated that PMX-DHP had a benefit on hospital survival when compared with conventional management (non-PMX-DHP) in matched patients of similar severity. A large multicenter prospective randomized trial is going now to confirm the efficacy of PMX-DHP treatment in septic shock.